Tempus AI, Inc. (NASDAQ:TEM) CEO Sells $6,844,836.80 in Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric P. Lefkofsky sold 84,640 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $80.87, for a total value of $6,844,836.80. Following the transaction, the chief executive officer now owns 4,964,820 shares in the company, valued at $401,504,993.40. This represents a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Tempus AI Stock Performance

Shares of TEM stock traded down $8.57 during mid-day trading on Friday, reaching $68.15. The stock had a trading volume of 14,356,143 shares, compared to its average volume of 14,342,920. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $91.45. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The business has a 50-day simple moving average of $49.75 and a 200 day simple moving average of $51.44.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Bank of America increased their price objective on Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a report on Friday, December 13th. Stifel Nicolaus cut Tempus AI from a "buy" rating to a "hold" rating and boosted their price target for the company from $45.00 to $65.00 in a research report on Monday, November 11th. TD Cowen reaffirmed a "buy" rating and set a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. William Blair downgraded shares of Tempus AI from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $58.55.

Hedge Funds Weigh In On Tempus AI

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Operose Advisors LLC purchased a new position in shares of Tempus AI during the 4th quarter worth approximately $25,000. First Horizon Advisors Inc. purchased a new position in Tempus AI during the third quarter worth $30,000. Farther Finance Advisors LLC acquired a new position in shares of Tempus AI in the fourth quarter worth $34,000. Prestige Wealth Management Group LLC lifted its position in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after acquiring an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at $49,000. Institutional investors and hedge funds own 24.22% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.